Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183908
Title: | Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry |
Author: | Balaz, David Wikman-Jorgensen, Philip Erick Galvañ, Vicente Giner Rubio Rivas, Manuel Miguel Campo, Borja de López, Mariam Noureddine López Caleya, Juan Francisco Gómez Huelgas, Ricardo Pesqueira Fontán, Paula María Méndez Bailón, Manuel Fernández Garcés, Mar Fernández Cruz, Ana García García, Gema María Rhyman, Nicolás Corral Gudino, Luis Lozano Rodríguez-Mancheño, Aquiles Chica, María Navarro de la Torregrosa García, Andrea Alcalá, José Nicolás Díaz Jiménez, Pablo Royo Trallero, Leticia Esther Comas Casanova, Pere Millán Núñez-Cortés, Jesús Casas Rojo, José Manuel SEMI-COVID-19 Network |
Keywords: | COVID-19 Corticosteroides COVID-19 Adrenocortical hormones |
Issue Date: | 8-Oct-2021 |
Publisher: | MDPI AG |
Abstract: | Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236-996) mu g/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) mu g/dL; p < 0.001), and lower Sp0(2)/Fi0(2) (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm10194610 |
It is part of: | Journal of Clinical Medicine, 2021, vol 10, num 19 |
URI: | http://hdl.handle.net/2445/183908 |
Related resource: | https://doi.org/10.3390/jcm10194610 |
ISSN: | 2077-0383 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-10-04610-v2.pdf | 996.92 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License